Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04491188
Other study ID # 01082018
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 8, 2018
Est. completion date May 3, 2018

Study information

Verified date July 2020
Source Lipscomb University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Active males and females consumed a probiotic for 28-days. Before and after the intervention period, participants reported to the lab in a fasted state where they consumed 25 grams of whey protein. Following drink consumption, participants provided blood draws at 15-minute intervals. Blood samples were analyzed for amino acid concentrations.


Recruitment information / eligibility

Status Completed
Enrollment 22
Est. completion date May 3, 2018
Est. primary completion date May 3, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 34 Years
Eligibility Inclusion Criteria:

- 18-34 years old Participants must have at least 1 year of resistance training experience.

- Free of any physical limitations, medications, and supplements that may affect performance, as determined by a health and activity questionnaire.

- Are free of musculoskeletal injuries

- Are not taking medications that may interfere with study measurements

Exclusion Criteria:

- Taking any other nutritional supplement or performance enhancing drug.

- Any chronic illness that causes continuous medical care

- Taking any other nutritional supplement or performance enhancing drug.

- Any chronic illness that causes continuous medical care.

Study Design


Related Conditions & MeSH terms

  • Focus of Study is Amino Acid Appearace in Blood

Intervention

Dietary Supplement:
Bacillus subtilis DE111
1 x10-9 CFU Bacillus subtilis DE111 probiotic
Placebo
Maltodextrin placebo

Locations

Country Name City State
United States Jeremy Townsend Nashville Tennessee

Sponsors (2)

Lead Sponsor Collaborator
Lipscomb University Deerland Enzymes

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Plasma Amino Acid response We measured plasma amino acid concentrations before and after the 28-day intervention 28-days
Secondary Body Composition Body Fat Percentage (%) will be monitored before and after the intervention via Bioelectical Impedance Analysis. 28-days